BIOCYTOGEN PHARMA. H YC1
Research BIOCYTOGEN PHARMA. H YC1 (I54) on Bullrun: market cap EUR 2.93B, P/E 60.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerI54
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 2.93B
- P/E60.0
- Financial periodFY2025
- RevenueCNY 1.38B
- Revenue growth40.6%
- Net incomeCNY 173.20M
- Free cash flowCNY 282.43M
- Gross margin75.8%
Valuation Snapshot
latest market cap is EUR 2.93B; P/E is 60.0.
Peer valuation comparison
Latest P/E is 60x versus a Healthcare sector median of 24.46x (145.3% above).
Latest P/E is 60x versus a China median of 10.67x (462.2% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 1.38B | CNY 173.20M | CNY 282.43M | 75.8% | n/a | CNY 1.56B | CNY 584.09M | CNY 2.17B |
| FY2024 | CNY 980.45M | CNY 33.54M | CNY 174.12M | 77.7% | 0.08 | CNY 381.18M | CNY 570.28M | CNY 834.06M |
| FY2023 | CNY 716.91M | -CNY 382.95M | -CNY 203.26M | 70.6% | -0.96 | CNY 399.60M | CNY 544.11M | CNY 785.89M |
| FY2022 | CNY 533.88M | -CNY 601.95M | -CNY 543.54M | 73.4% | -1.58 | CNY 603.07M | CNY 415.28M | CNY 1.15B |
| FY2021 | n/a | n/a | n/a | n/a | -1.38 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | EUR 2.93B | 60.0 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About BIOCYTOGEN PHARMA. H YC1
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BIOCYTOGEN PHARMA. H YC1's market cap?
BIOCYTOGEN PHARMA. H YC1's market capitalization is EUR 2.93B.
What is BIOCYTOGEN PHARMA. H YC1's P/E ratio?
BIOCYTOGEN PHARMA. H YC1's price-to-earnings (P/E) ratio is 60.0.
What does BIOCYTOGEN PHARMA. H YC1 do?
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other.